3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Status
Unknown
1
Suspended
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Stomach Neoplasms
30
Carcinoma, Hepatocellular
22
Small Cell Lung Carcinoma
15
Colorectal Neoplasms
14
Carcinoma, Non-Small-Cell Lung
14
Sarcoma
13
Ovarian Neoplasms
12
Breast Neoplasms
12
Triple Negative Breast Neoplasms
9
Nasopharyngeal Carcinoma
9
Esophageal Squamous Cell Carcinoma
9
Cholangiocarcinoma
9
Biliary Tract Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Osteosarcoma
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Head and Neck Neoplasms
5
Esophageal Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
4
Neoplasms
4
Melanoma
4
Solid Tumor
3
Recurrence
3
Neoplasm Metastasis
3
Liver Neoplasms
3
Glioma
3
Gastric Adenocarcinoma
3
Carcinoma, Adenoid Cystic
3
Interventions
Amifostine
10
Cisplatin
8
Radiotherapy
7
Etoposide
6
Cyclophosphamide
4
Carboplatin
4
Paclitaxel
3
pegfilgrastim
2
camrelizumab
2
apatinib
2
Mitoxantrone
2
Filgrastim
2
Drug Therapy
2
Cytarabine
2
sodium thiosulfate
1
sargramostim
1
pazopanib
1
icotinib
1
glucarpidase
1
etoposide phosphate
1
denileukin diftitox
1
Vitamin E
1
Triptorelin Pamoate
1
Tocopherols
1
Thiotepa
1
Tegafur
1
Taxes
1
Surgical Procedures, Operative
1
Silymarin
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Drug-Related Side Effects and Adverse Reactions
×
apatinib
×
Clear all
NCT04824352
2024-05-14
AIEO
Peking University People's Hospital
Phase 2
Suspended
44 enrolled
NCT04351308
2020-05-19
MAPAC
Peking University People's Hospital
Phase 2
Unknown
60 enrolled